National Library of Medicine; Notice of Closed Meetings, 8203-8204 [2021-02278]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices
lines 2–3, change ‘‘Am. J. Physiol. Lung
Cell. Mol. Biol.’’ to ‘‘Am. J. Resp. Cell.
Mol. Biol.’’
5. On page 60098, second column, in
FR Doc. 2019–24291, sixth paragraph,
lines 1 and 3, change ‘‘J. App. Physiol.’’
to ‘‘J. Appl. Physiol.’’
6. On page 60098, second column, in
FR Doc. 2019–24291, twenty-third
paragraph, lines 1–2, change ‘‘Am. J.
Physiol. Lung Cell. Mol. Biol. 2011b
paper’’ to ‘‘Am. J. Physiol. Lung Cell.
Mol. Physiol. 2011;301(3):L327–L333.’’
Dated: January 29, 2021.
Wanda K. Jones,
Acting Director, Office of Research Integrity.
[FR Doc. 2021–02272 Filed 2–3–21; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Yibin Lin, Ph.D. (Respondent), former
postdoctoral fellow, McGovern Medical
School, University of Texas Health
Science Center (UTHealth). Respondent
engaged in research misconduct in
research supported by U.S. Public
Health Service (PHS) funds, specifically
National Institute of Allergy and
Infectious Diseases (NIAID), National
Institutes of Health (NIH), grant R01
AI125216. The administrative actions,
including debarment for a period of ten
(10) years, were implemented beginning
on January 7, 2021, and are detailed
below.
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr. P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Yibin Lin, Ph.D., University of Texas
Health Science Center: Based on the
report of an assessment conducted by
UTHealth, Respondent’s admission, and
analysis conducted by ORI in its
oversight review, ORI found that Dr.
Yibin Lin, former postdoctoral fellow,
McGovern Medical School, UTHealth,
engaged in research misconduct in
research supported by PHS funds,
specifically NIAID, NIH, grant R01
AI125216.
VerDate Sep<11>2014
17:13 Feb 03, 2021
Jkt 253001
ORI found that Respondent engaged
in research misconduct by knowingly
and intentionally falsifying, fabricating,
and plagiarizing data and text reported
in the following published papers,
which have been retracted, and
manuscripts:
Published Papers
• Efficient Method for Genomic DNA
Mutagenesis in E. coli. bioRxiv 2020.
doi: https://doi.org/10.1101/
2020.05.16.097097.
• A simple and efficient method for
in vitro site directed mutagenesis.
bioRxiv 2020. doi: https://doi.org/
10.1101/2020.05.16.100107.
• A restriction-free method for gene
reconstitution. bioRxiv 2020. doi:
https://doi.org/10.1101/
2020.05.20.107631.
• Efficient Method for Protein
Crystallization. bioRxiv 2020. doi:
https://doi.org/10.1101/
2020.05.24.113860.
• Rice Tolerance to Drought is
Complex Both Physiologically and
Genetically. bioRxiv 2020. doi: https://
doi.org/10.1101/2020.08.19.258293.
• ITS2 Pretrial Gene Identification
Related to Seed and Flower
Identification for Cyclea barbata.
bioRxiv 2020. doi: https://doi.org/
10.1101/2020.08.20.259804.
Manuscripts Submitted to bioRxiv in
2020 and Not Published
• Analysis of the Deduced Amino
Acid Sequence of Lectin-like Protein.
• Comprehensive proteomic
characterization of ovarian tumors.
• Insight into the membrane protein
localization and antibiotic resistance by
fluorescence microscopy.
• Invariant States of the Algebra of
Observables.
• The Biochemical Analysis the
Expression Levels of Pre-synaptic, Postsynaptic, Nuclear and Mitochondrial
Markers.
• The Overall Difference Analysis of
Antioxidant of Isoflavone from Three
Kinds of Soybean Stems.
• The Overall Difference Analysis of
Antioxidant of Isoflavone from Three
Kinds of Tomato.
Manuscript Rejected by bioRxiv and
Resubmitted to medRxiv in 2020
• Invariant States of the Algebra of
Observables.
ORI finds that Respondent knowingly
and intentionally falsified, fabricated,
and plagiarized the whole content of six
(6) papers and eight (8) manuscripts,
falsely created fictitious author names
and affiliations without listing himself
as an author to disguise himself from
being the offender, and submitted them
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
8203
for publication in bioRxiv and medRxiv,
open access preprint repositories, by
falsely assembling random paragraphs
of text, tables, and figures from previous
publications and manuscripts to
improve his citation metrics.
Dr. Lin entered into a Voluntary
Exclusion Agreement (Agreement) and
agreed to the following:
(1) Because the Respondent also
attempted to deceive the online
publication sites bioRxiv and medRxiv
by creating fictitious author names and
affiliations without listing himself as an
author, Respondent agreed to exclude
himself voluntarily for a period of ten
(10) years beginning on January 7, 2021,
from any contracting or subcontracting
with any agency of the United States
Government and from eligibility for or
involvement in nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions’’ pursuant to HHS’
Implementation (2 CFR part 376) of
OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’); and
(2) Respondent agreed to exclude
himself voluntarily from serving in any
advisory capacity to PHS including, but
not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant for
a period of ten (10) years, beginning on
January 7, 2021.
Dated: January 29, 2021.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2021–02273 Filed 2–3–21; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\04FEN1.SGM
04FEN1
8204
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; G08.
Date: March 26, 2021.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D.,
Scientific Review Officer, Extramural
Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 500, Bethesda,
MD 20892–7968, 301–827–7077, tsapl@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: January 26, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02278 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2:
Research Answers to NCI Provocative
Questions.
Date: February 23, 2021.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W104, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: David G. Ransom, Ph.D.,
Chief, Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W104,
Rockville, Maryland 20850, 240–276–6351,
david.ransom@nih.gov.
VerDate Sep<11>2014
17:13 Feb 03, 2021
Jkt 253001
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
(P50) Review V.
Date: February 25–26, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W120, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Majed M. Hamawy, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W120,
Rockville, Maryland 20850, 240–276–6457,
mh101v@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Visualization Methods and Tools
Development for Enhancing Cancer
Moonshot Data (R33).
Date: March 10, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W108, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Rockville, Maryland 20850, 240–276–6343,
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–7: NCI
Clinical and Translational R21 and Omnibus
R03 Review.
Date: March 16–17, 2021.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W104, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: David G. Ransom, Ph.D.,
Chief, Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W104,
Rockville, Maryland 20850, 240–276–6351,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; 3D
Technologies to Accelerate HTAN.
Date: March 19, 2021.
Time: 9:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W556, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Kamal Datta, M.D.,
Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W556, Rockville, Maryland 20850,
240–276–6526, kamal.datta@nih.gov.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Institute Special Emphasis Panel; R01(IARC)
Conference Grant Review.
Date: April 6, 2021.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W552, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Jeanette Irene Marketon,
Ph.D., Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W552, Rockville, Maryland 20850,
240–276–6780, jeanette.marketon@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 26, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02289 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Council of Research Advocates.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: March 10–11, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: Welcome and Chairwoman’s
Remarks, NCI Updates, Legislative Update,
and Director’s Update.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Amy Williams, NCI Office
of Advocacy Relations, National Cancer
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 86, Number 22 (Thursday, February 4, 2021)]
[Notices]
[Pages 8203-8204]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02278]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which
[[Page 8204]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Library of Medicine Special Emphasis
Panel; G08.
Date: March 26, 2021.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D., Scientific Review
Officer, Extramural Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 500, Bethesda, MD 20892-7968, 301-827-
7077, [email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.879,
Medical Library Assistance, National Institutes of Health, HHS)
Dated: January 26, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-02278 Filed 2-3-21; 8:45 am]
BILLING CODE 4140-01-P
